Last updated: March 8, 2026
What Is the Scope and Content of Patent AU2019202674?
Patent AU2019202674, titled "Compounds and Methods for Treating Diseases," is a pharmaceutical patent granted to cover specific chemical compounds and their therapeutic applications. The patent was filed in Australia, with application number AU2019202674, with priority claimed from an earlier international application under the Patent Cooperation Treaty (PCT).
The patent claims:
- A class of chemical compounds characterized by a core structure, notably a substituted heteroaryl group linked to a phenyl ring with various substituents.
- Methods of synthesizing these compounds.
- Pharmaceutical compositions comprising the compounds.
- Uses of the compounds for treating specific disorders, primarily neurological and inflammatory diseases.
The patent claims are structured into four main categories:
- Compound claims: Covering the chemical entities, including specific substitutions on the core structure.
- Method claims: Describing processes for manufacturing the compounds.
- Formulation claims: Relating to compositions that include the compounds.
- Use claims: Covering the therapeutic applications, especially in treating diseases such as multiple sclerosis, Alzheimer’s disease, and other neurodegenerative conditions.
How Broad Are the Claims?
The scope of patent AU2019202674 is moderately broad, primarily because it claims a genus of compounds with defined core structures and variable substituents. The claims specify:
- A class of heteroaryl derivatives with particular substitution patterns.
- Methods of preparation.
- Therapeutic use in neuroinflammatory and neurodegenerative disorders.
The variability in substituents allows coverage over multiple compound variants, which can be advantageous for protecting a range of similar compounds with potential therapeutic effects.
In comparison to similar patents in this area, the claims do not extend to all possible heteroaryl derivatives but focus on a specific subset, providing a balance between breadth and specificity.
Patent Landscape Context
Major Players and Related Patents
The patent landscape surrounding similar compounds and therapeutic targets includes key patent families held by pharmaceutical companies such as Novartis, Roche, and Biogen. Noteworthy related patents feature:
- Patent families on Janus kinase (JAK) inhibitors for neurodegenerative diseases.
- Patents on BACE inhibitors for Alzheimer’s treatment.
- Patent applications covering specific heteroaryl compounds with anti-inflammatory activity.
AU2019202674 is part of this landscape, focusing on a novel subclass of heteroaryl derivatives with claimed use in neuroprotection and anti-inflammatory therapy.
Patentability and Novelty
The patent office granted this patent based on the novelty of the claimed compounds and their specific use profiles. The Patent Examiner examined prior art, including international patent applications, scientific publications, and previous patents. No identical compounds or uses were cited during prosecution.
Remaining Freedom-to-Operate Considerations
Potential patent infringement risks depend on:
- The scope of claims in competing patents.
- The specific chemical substitutions involved.
- The therapeutic applications claimed.
Companies reformulating compounds or developing non-overlapping chemical variants may avoid infringement.
Patent Term and Data Exclusivity
- The patent is granted with a standard term of 20 years from the filing date.
- Data exclusivity may extend the market exclusivity for the first approved product using these compounds for five years in Australia.
Enforceability and Litigation Status
As of the latest update, no litigation activities have been publicly reported related to AU2019202674. Enforcement could be challenged if competitors develop markedly different compounds or alternative therapeutic pathways.
Strategic Implications for R&D and Commercialization
- The patent’s scope supports development of multiple compounds targeting neurodegenerative diseases.
- The claims provide protection for both manufacturing processes and therapeutic use, facilitating a broad commercial strategy.
- Alignment with ongoing clinical trials for neuro-inflammatory indications could enhance patent value.
- Competition from existing patents and prior art necessitates careful freedom-to-operate analysis before commercialization.
Summary Table
| Aspect |
Details |
| Patent Number |
AU2019202674 |
| Filing Date |
August 22, 2019 |
| Grant Date |
September 2022 |
| Patent Term |
20 years from filing (August 22, 2019) |
| Claim Types |
Compound, synthesis, formulation, therapeutic use |
| Main Focus |
Heteroaryl derivatives for neuroinflammatory and neurodegenerative diseases |
| Patent Landscape Status |
Part of broader patent family targeting neurotherapy |
| Enforceability |
No reported litigation; enforceability depends on breadth of claims |
Key Takeaways
- Patent AU2019202674 covers a specific subclass of heteroaryl compounds, with claims extending to synthesis, formulation, and therapeutic applications.
- Scope balances specificity with breadth, protecting multiple variants within the defined chemical class.
- It resides within a competitive landscape of neurodegenerative and inflammatory disease patents.
- The patent provides a relatively broad strategic platform for development in neurological therapeutics.
- Due diligence on overlapping patents is essential for freedom-to-operate analysis.
Frequently Asked Questions
1. How does the scope of AU2019202674 compare to similar patents?
It focuses on a defined subclass of heteroaryl derivatives with specific substitution patterns, making it narrower than broad chemical genus claims but sufficiently broad to cover multiple compounds with potential therapeutic utility.
2. Can this patent be challenged based on prior art?
Yes; if prior art discloses identical or substantially similar compounds or uses, the patent may be subject to validity challenges. However, examination found no identical prior disclosures.
3. What are the key strategic benefits of this patent?
It provides protection across multiple stages: compound synthesis, formulation, and therapeutic application, enabling comprehensive market exclusivity for drugs developed within its scope.
4. How likely is this patent to be infringed upon?
Infringement risks depend on the development of compounds within its claimed chemical class and therapeutic claims. Companies developing similar compounds must analyze other patents for potential overlap.
5. What is the expiration date, and when can generic competition enter?
The patent expires 20 years after its filing date, which is August 22, 2039. Generic entry may occur after patent expiry unless supplementary exclusivities are granted.
References
[1] Australian Patent Office. (2022). Patent AU2019202674. Retrieved from IP Australia database.
[2] WIPO. (2020). International Patent Application WO2020225325A1. Retrieved from WIPO PATENTSCOPE.
[3] European Patent Office. (2021). Patent EP3141524B1. Retrieved from EPO Espacenet.
[4] Furfari, G., et al. (2022). "Heteroaryl derivatives for neurodegenerative diseases," J. Med. Chem., 65(4), 2450-2467.
[5] World Health Organization. (2021). "Neurodegenerative and neurological disorders," Global Health Estimates.
